Zai Lab raises $250M in PIPE to fund cancer drug development
What's the deal? Zai Lab, a biopharma company listed on Nasdaq and the Hong Kong exchange, has raised about $250 million in a private investment in public equity (PIPE) financing led by TCGXDealroom has a profile for this one. Try Dealroom →. The deal covers 11,340,000 American Depositary Shares priced at $22.04 each, and is expected to close on or about October 27, 2026.
Who's in? Alongside lead investor TCGX, the round drew new and existing backers including abrdn World Healthcare Fund, ADAR1 Capital ManagementDealroom has a profile for this one. Try Dealroom →, Balyasny Asset ManagementDealroom has a profile for this one. Try Dealroom →, Cormorant Asset Management, Frazier Life SciencesDealroom has a profile for this one. Try Dealroom →, RA Capital Management, RTW InvestmentsDealroom has a profile for this one. Try Dealroom →, Sirenia Capital ManagementDealroom has a profile for this one. Try Dealroom →, Wellington Management, and Woodline PartnersDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Zai Lab plans to use the net proceeds mainly to fund global development of zocilurtatug pelitecan, known as zoci. It is an antibody-drug conjugate that targets Delta-like ligand 3 (DLL3).
Why it matters: Leerink PartnersDealroom has a profile for this one. Try Dealroom → is acting as exclusive placement agent, with Ropes & Gray as legal advisor. The ADSs were not registered under the Securities Act, and Zai Lab has agreed to file a resale registration statement with the Securities and Exchange Commission.
The signal: At roughly $250 million, the raise sits near the top of the market — above the 94th percentile of all post-IPO equity rounds in health, based on 6,289 comparable deals. The scale of investor interest underscores continued appetite for late-stage oncology assets.
Read more: wallstreet-online.de
Image credit: National Institutes of Health (NIH)
